

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/596,851	First Named Inventor: Brown
371 Filing Date: May 29, 2007	Attorney Docket No.: 101260-1P US
Examiner: Leeser, Erich A.	Group Art Unit : 1624
Customer No.: 22466	Confirmation No.: 1341
Title: Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

Assignee, AstraZeneca AB, duly organized under the laws of Sweden and having its principal place of business at SE-151 85 Sodertalje, Sweden, represents it is the assignee of the entire right, title, and interest in and to the above-identified Application No. 10/596,851, filed January 5, 2005 (371 filing date of May 29, 2007) for Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof in the names of William Brown and Andrew Griffin, as indicated by the assignment duly recorded in the United States Patent and Trademark Office at Reel 018411, Frame 0436 on October 19, 2006. Assignee, AstraZeneca AB, further represents it is the assignee of the entire right, title, and interest in and to U.S. Patent No. 7,253,173, as indicated by the assignment(s) duly recorded in the United States Patent and Trademark Office at Reel 016565, Frame 0687 on July 25, 2005.

To obviate a double patenting rejection, Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior patent No. 7,253,173. Assignee hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent

granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, Assignee does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that the prior patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated before the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Please charge the \$140.00 fee due in accordance with 37 C.F.R. § 1.20(d) to Deposit Account No. 26-0166, referencing Attorney Docket No. 101260-1P US.

The undersigned is an attorney of record.

Respectfully submitted,

AstraZeneca Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington, DE-19850-5437
Phone No: 302-885-4269

/Jacqueline M. Cohen/
Name: Jacqueline M. Cohen
Dated: November 7, 2008
Reg. No: 51,574